It is an unfortunate fact that the world is dealing with a second hidden epidemic: The Opioid Crisis. Luckily, MindMed ( MMED/ MMEDF ) has a solution: 18-MC. This Psychedelic Medicines company, which may soon be uplisted to the Nasdaq, is testing it’s ibogaine derivative to heal those effected by opioid addiction, whether from fentanyl or doctors’ prescriptions. We may have a light at the end of the tunnel, and the Opioid Epidemic may be defeated. This makes MindMed one of the best stocks for 2021. How much could this be worth? Tune in to find out!
Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF #MindMedNews #OpioidEpidemic #OpioidCrisis #MindMedStock #18MC #18-MC #PsychedelicStocks
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.